Clinical Cancer Investigation Journal

ORIGINAL ARTICLE
Year
: 2019  |  Volume : 8  |  Issue : 3  |  Page : 84--89

Bevacizumab and capecitabine in relapsed platinum-resistant epithelial carcinoma of ovary: A retrospective study


Amitabha Chakrabarti, Santu Mondal, Soumita Poddar, S K M D Rejakul Islam 
 Department of Radiotherapy, Murshidabad Medical College and Hospital, Berhampore, West Bengal, India

Correspondence Address:
Santu Mondal
Flat-5/C, Pabitra Apartment, 50/1, A. C. Road, Indraprastha, Post Office, Murshidabad, Berhampore - 742 101, West Bengal
India

Background: Relapsed platinum-resistant epithelial carcinoma of the ovary is a disease with a dismal prognosis. Bevacizumab and capecitabine have been used in carcinoma of ovary both as a single agent and with other chemotherapeutic medicine. A retrospective study has been performed to assess the efficacy of bevacizumab + capecitabine in relapsed platinum-resistant epithelial carcinoma of the ovary. Materials and Methods: Patients who suffered from relapsed platinum-resistant epithelial carcinoma of the ovary and received bevacizumab and capecitabine were included in the present study. The primary objective of this study was to assess response rate and progression-free survival (PFS). Treatment: Patients received capecitabine at a dose of 1250 mg/m2 twice daily from day 1 to day 14 in each cycle. Bevacizumab was given at a dose of 7.5 mg/kg on day 1 in each cycle. The cycle was repeated in every 3 weeks. Response evaluation was done using the Response Evaluation Criteria in Solid Tumor criteria and by Rustin criteria. Statistical Analysis: Statistical analysis was done using statistical software (SPSS 16, SPSS for Windows, SPSS Inc., Chicago, IL, USA). Results: We analyzed the data of 32 patients. The PFS was 10.51 (95% confidence interval [CI], 8.65–12.37) months. The overall survival (OS) was 20.53 (95% CI, 17.21–23.85) months. Four (12.5%) patients achieved complete response. Eighteen (56.25%) patients achieved partial response. The response rate was 68.75%. Four (12.5%) patients had progressive disease. Conclusion: Response rate, PFS, and OS of patients in this study are comparable to those of other published studies. Hence, bevacizumab + capecitabine can be used in relapsed platinum-resistant carcinoma of the ovary. The incidence and severity of bevacizumab-induced side effects are relatively lower in this study. Hence, bevacizumab can be given at a lower dose with comparable efficacy and tolerable side effects.


How to cite this article:
Chakrabarti A, Mondal S, Poddar S, Rejakul Islam S K. Bevacizumab and capecitabine in relapsed platinum-resistant epithelial carcinoma of ovary: A retrospective study.Clin Cancer Investig J 2019;8:84-89


How to cite this URL:
Chakrabarti A, Mondal S, Poddar S, Rejakul Islam S K. Bevacizumab and capecitabine in relapsed platinum-resistant epithelial carcinoma of ovary: A retrospective study. Clin Cancer Investig J [serial online] 2019 [cited 2019 Aug 17 ];8:84-89
Available from: http://www.ccij-online.org/article.asp?issn=2278-0513;year=2019;volume=8;issue=3;spage=84;epage=89;aulast=Chakrabarti;type=0